Please login to the form below

Not currently logged in
Email:
Password:

Hans Lennernas joins board of CMO Recipharm

He is currently professor of biopharmaceuticals at Uppsala University

Sweden-based contract manufacturing organisation (CMO) Recipharm has appointed Professor Hans Lennernäs to its board of directors.

Prof Lennernäs is currently a professor of biopharmaceuticals at Uppsala University in Sweden, where he manages an Innovative Medicines Initiative (IMI) project called OrBiTo, which aims to improve the delivery of oral drugs.

Other industry experience includes serving as principle investigator in a collaborative project between US drug regulator the FDA, the University of Michigan and the Medical Product Agency in Sweden to develop a new guideline for the biopharmaceuticals classification systems.

Prof Lennernäs has also helped to launch several life sciences companies, including DuoCort Pharma and LIDDS.

“We are very pleased to welcome a board member of Hans Lennernäs calibre,” said Maria Lundberg, manager of Recipharm, which supplies pharma companies with products such as solid dose medicines, granulates and powders, sterile liquids and lyophilisates, hormones, oral liquids, sprays and dry powder inhalers.

“His track record of successfully inventing and developing several novel drug delivery systems that are currently in pre-clinical phase and in preparation for phase I, II and III clinical trials, makes him an excellent addition to the board.”

6th February 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics